The levonorgestrel-releasing intrauterine system (LNG-IUS) has proven to be the most effective medical treatment in reducing the amount of menstrual blood loss. However, the molecular mechanisms underlying menorrhagia and/or accounting for the therapeutic effect of the LNG-IUS are still obscure. In this study, we used immunohistochemistry to compare the distribution of sex steroid receptors and the proliferation marker Ki-67 in the endometria of women with and without menorrhagia before and after 6 and 12 months of treatment with an LNG-IUS. The study sample included 67 women (aged 35-49 years) who had spontaneous ovulatory cycles. In women with menorrhagia, secretory phase endometrium exhibited more proliferative activity than in women without menorrhagia. No significant differences were found in the immunoreactivity of the oestrogen or progesterone receptors in women either with or without menorrhagia suggesting that, in addition to endocrine hormones, other factors are involved in the regulation of endometrial proliferation and menstrual blood loss. A total of 35 women were treated with LNG-IUS. After 6 months use of an LNG-IUS, the immunoreactivity of both epithelial and stromal progesterone receptors, as well as those of epithelial Ki-67 declined, and no differences were detectable between the women in the menorrhagia and control groups. Breakthrough bleeding remained a problem for nine (26%) LNG-IUS users, with no association with the pre-treatment amount of bleeding. No significant differences were found in the parameters studied between the women with and without breakthrough bleeding 6 months after insertion of an LNG-IUS.
Introduction
which releases 20 µg of levonorgestrel over a 24 h period, was originally designed for contraception but it has now Excessive menstrual bleeding (ജ80 ml per period) is one of proven to be effective in the treatment of menorrhagia the most common problems in gynaecology (Coulter et al., (Andersson et al., 1990; Luukkainen and Toivonen, 1995) . Data 1989). Although new diagnostic methods have improved the from studies regarding use of the LNG-IUS for contraception clinical triage of menorrhagia,~50% of the cases display suggest that its mechanism of action is associated with atrophy no underlying pathology (Rees, 1987) . The mechanisms of of epithelial cells (Silverberg et al., 1986) . Functional alteradysfunctional menorrhagia are complex and poorly understood.
tions have been shown to include down-regulation of endometSteroid hormones are the major endocrine regulators of endorial progesterone receptors (PR) and proliferation (Critchley metrial function, exerting their effects through cellular recepet al., 1998a; Salmi et al., 1998a) as well as suppression of tors which, when activated, induce gene expression of local insulin-like growth factor 1 (IGF-I) mRNA, with concomitant regulatory factors. The interplay between oestrogen, progesterstimulation of IGF-II and IGF-binding protein 1 (IGFBP-1) one, their receptors and local factors in endometrial function mRNAs (Rutanen et al., 1997) . However, no studies have been remains unclear. Contraceptive pills and the levonorgestrelconducted on the effect of the LNG-IUS on endometrial steroid releasing intrauterine system (LNG-IUS) reduce the amount receptors and the proliferation marker Ki-67 in women with of menstrual bleeding (Andersson and Rybo, 1990; Milsom menorrhagia. et al., 1991) , suggesting that hormones are involved in the All progestogen-only contraceptives, including the LNGregulation of menstrual blood loss. On the other hand, cyclic IUS, are associated with the problem of breakthrough bleeding progestogen has no effect on menorrhagia (Higham and Shaw, (Kovacs, 1996) . This suggests that an imbalance in either sex 1991), indicating that the underlying mechanism is not progessteroid concentrations or their receptors may disturb the control terone deficiency alone. Reports on the expression of sex of mechanisms responsible for the prevention of aberrations steroid receptors in the endometria of women with menorrhagia in normal bleeding patterns (Critchley et al., 1998b) . To our are controversial.
knowledge, there have been no studies on sex steroid receptors The 19-nortestosterone derivative, levonorgestrel, has a in the endometria of women with and without breakthrough bleeding during use of the LNG-IUS. strong progestin effect on the endometrium. The LNG-IUS, with ERα, but not with ERβ. Avidin-biotin-peroxidase (ABC)
The aim of our study was to examine the effect of the LNGstaining was carried out by using Strept ABComplex/HRP Duet, IUS on the distribution of sex steroid receptors and Ki-67 in Mouse/Rabbit (Dako) for both sex steroid receptors and Vectastain the endometria of women with menorrhagia. In addition, we ABC kits (Vector Laboratories Inc., Burlingame, CA, USA) for Ki- wanted to study the same variables in women with breakthrough 67 as shown in our previous studies (Salmi et al., 1996 (Salmi et al., , 1998a bleeding during use of the LNG-IUS.
The formalin-fixed, paraffin wax-embedded tissue sections (5 µm) were deparaffinized in xylene and rehydrated by sequential incubation in decreasing concentrations of ethanol. The deparaffinized tissue
Materials and methods
sections were pre-treated with 10 mmol/l citric acid (pH 6.0) in a A randomized multicentre trial, comparing hysterectomy with the microwave oven for 2ϫ5 min and left in the buffer at room LNG-IUS for the treatment of menorrhagia, was started at all temperature for 20-60 min before the staining procedure. All washings five university hospitals in Finland in September 1994. The study were performed using 0.01 mol/l phosphate-buffered saline (PBS), population consisted of women aged 35-49 years, who were referred pH 7.4. The sections were treated with 0.8% hydrogen peroxide in to the gynaecology outpatient clinics because of menorrhagia. Patients methanol for 5 min to quench the endogenous peroxidase activity, with endometrial or ovarian pathology (examined physically and by and blocked with normal goat (ER, PR) or horse (Ki-67) serum (1:20) vaginal ultrasonography) were excluded, as well as those who had (Dako) for 20 min to reduce non-specific binding of antibodies. The previous malignancies, urinary or bowel symptoms, or pain due to primary antibody diluted in PBS (ER 1:800, PR 1:500, Ki-67 1:300) large fibroids. Those women who had taken hormonal preparations was added and the sections were incubated overnight at 4°C. After during the previous month, who had anovulatory cycles or a patholorinsing, biotinylated second-step goat anti-mouse immunoglobulins gical finding in endometrial biopsy, who were menopausal (FSH Ͼ30
were added (ER, PR 1:100, Ki-67 1:200) (Dako), followed 30 min IU/l) or who failed to measure their menstrual blood loss (MBL) later by an ABC reagent (1:100). After 30 min the sites of antibody were also excluded. A total of 67 women, 41 women with menorrhagia binding were demonstrated by developing the peroxidase reaction and 26 without menorrhagia (controls) were enrolled at Helsinki with 3-amino-9-ethyl-carbazole in 50 mmol/l acetate buffer (pH 5.0) University Central Hospital between September 1994 and September containing 0.03% hydrogen peroxide, for 15 min. The sections were 1997. This study was approved by the Ethics Committee of Helsinki rinsed with water and counterstained with diluted haematoxylin. For University Hospital and all women gave their informed consent.
each tissue section, a negative control was stained with mouse MBL was measured by an alkaline haematin method as described immunoglobulin (Vector Laboratories Inc.), used at the same concenpreviously (Hallberg et al., 1964; Hurskainen et al., 1998) . In order tration as the first antibody. to demonstrate the validity of our MBL measurement, serum ferritin Insulin-like growth factor-binding protein 1 (IGFBP-1 ) immunoconcentrations were measured by direct chemiluminescent immunohistochemistry was used to verify the endometrial response to assay (Chiron Diagnostics, Halstead, UK). True menorrhagia was levonorgestrel. Immunoreactive IGFBP-1 was detected by using defined as MBL of ജ80 ml per period. Women with a measured monoclonal mouse antibodies to human IGFBP-1 (Mab 6303; Medix MBL of Ͻ80 ml were taken to be controls.
Biochemica, Kauniainen, Finland) (Rutanen et al., 1988) as previously Endometrial samples were obtained from all 67 women, using a described (Rutanen et al., 1991) . disposable biopsy curette (Pipelle; Laboratoire CCD, Paris, France),
The immunohistochemical data was analysed by three independent during the first out-patient visit, either in the proliferative or secretory observers. Ten fields of cells of a tissue section (magnification ϫ200) phase of the cycle. The phase of the menstrual cycle was determined were examined, and only nuclear staining was considered specific to on the basis of menstrual history and confirmed by histological dating ER, PR and Ki-67, and cytoplasmic staining specific to IGFBP-1. carried out by the pathologist according to established criteria (Noyes The immunostaining intensity of all tissue sections as regards sex et al., 1975) . A LNG-IUS was inserted into the uterus of 24 women steroid receptors and Ki-67 was scored on a four-point scale, where with menorrhagia and 11 controls. Endometrial samples were collected 0 ϭ no staining; 1 ϭ mild staining; 2 ϭ moderate staining; and 3 ϭ for this study from 19 women with menorrhagia and from nine intense staining. IGFBP-1 was evaluated as being present or absent. controls 6 months after the insertion, and from 17 women (11 with and six without menorrhagia) 12 months after insertion. Since the Statistical analysis date of the menstrual cycle cannot be determined by histological
The data were analysed using non-parametric tests; the Manncriteria during use of the LNG-IUS, the data obtained after insertion Whitney test for non-dependent variables and the paired Wilcoxon were pooled, regardless of the phase of the menstrual cycle.
Signed Ranks test for data comparing women using a LNG-IUS. The Bleeding over 5 days apart from cyclical menstrual bleeding was associations between serum oestradiol and progesterone concentraconsidered as breakthrough bleeding. Five women from menorrhagia tions, and sex steroid receptors and Ki-67 were assessed by calculation group and four women from controls suffered breakthrough bleeding of Pearson's product-moment correlation coefficients. P Ͻ 0.05 was during the use of the LNG-IUS.
considered to be statistically significant. To check ovarian function, we measured serum FSH concentrations by an immunofluorometric method (Wallac, Turku, Finland), and serum oestradiol and progesterone concentrations by using 
endometria of women with and without menorrhagia
The expression of sex steroid receptors and the proliferation marker Characteristics of the subjects are shown in Table I . The scores in the endometrium was studied by immunohistochemistry, for immunoreactivity of sex steroid receptors and Ki-67 in the using monoclonal mouse antibodies to human. Oestrogen receptor endometrial samples obtained from women with and without (ER) (Daco ER; Dako, Glostrup, Denmark), progesterone receptor menorrhagia are shown in Table II . When both study groups (PR) (Novocastra Laboratories Ltd, Newcastle-upon-Tyne, UK) and were analysed together, the scores of immunoreactivity of sex Ki-67 (Pharmigen, San Diego, CA, USA). The antibody against PR detects A ϩ B isoforms of PR, and the antibody against ER reacts steroid receptors and Ki-67 were higher in proliferative phase than in secretory phase endometrium (ER, P ϭ 0.02; PR, P ϭ months' use of the LNG-IUS compared with proliferative endometrium prior to insertion (Wilcoxon test). A significant 0.0001; Ki-67, P ϭ 0.04) (Mann-Whitney test).
When comparing endometrial samples obtained from women decrease was also detected in the immunoreactivity of epithelial PR (P ϭ 0.03) and stromal PR (P ϭ 0.02) when biopsies with menorrhagia with those from controls, a significant difference was found in the immunoreactivity of epithelial obtained during LNG-IUS use were compared with biopsies collected prior to insertion from secretory endometrium. Ki-67 in secretory phase endometrium (P ϭ 0.04) (Table II) ; women with objective menorrhagia had higher scores for
Immunostaining scores for ER, PR and Ki-67 after 12 months use of the LNG-IUS were similar to those at 6 months, and Ki-67 than women with normal bleeding. No significant difference was detected in the immunoreactivity scores of no significant difference was detected at either timepoint between the women with and without menorrhagia (Table III) . either sex steroid receptors between the study groups (MannWhitney test).
After 6 months use of the LNG-IUS, no significant differences were found in immunoreactivity of endometrial sex Effect of the LNG-IUS steroid receptors and Ki-67 between women with (n ϭ 9) and without breakthrough bleeding (n ϭ 19). There was no A total of 35 women were treated with the LNG-IUS (24 with menorrhagia, 11 controls). Insertion of a LNG-IUS resulted in correlation between serum FSH, oestradiol or progesterone concentrations and immunoreactive ER, PR or Ki-67 (data widespread morphological changes in endometrial histology. After 6 months use, a decidual reaction in stromal cells not shown). and epithelial atrophy were seen in all endometrial samples available (19 menorrhagic, nine controls). The strength of Discussion decidualization varied from one region to another, throughout Our finding of higher immunoreactivity of sex steroid receptors the functional layer. All samples showed immunoreactive in proliferative phase than in secretory phase endometrium is IGFBP-1 in decidual cells as a sign of a decidual reaction in accordance with the results of previous studies (Lessey (Rutanen et al., 1997) . The scores for immunostaining of et al., 1988; Snijders et al., 1992; Critchley et al., 1993 ; Salmi epithelial PR (P ϭ 0.003), stromal PR (P ϭ 0.003) and et al., 1998a). epithelial Ki-67 (P ϭ 0.02) were significantly lower after 6
This study demonstrates, for the first time, higher immunoreactivity of the proliferation marker Ki-67 in the epithelium of secretory phase endometrium of menorrhagic women compared n ϭ 11 n ϭ 19 n ϭ 9 n ϭ 11 n ϭ 6 ER epithelial proliferative n ϭ 12 n ϭ 4 stronger in women with menorrhagia than in women with consistent with the results of previous studies (Critchley et al., 1998a; Salmi et al., 1998a) . In addition, there was some normal bleeding. Since no differences were found in either serum oestradiol concentrations or immunoreactive ER in the decline (but not significant) in ER immunoreactivity in both the epithelial and stromal compartments. This is also in keeping endometrium, it is possible that errors in autocrine/paracrine factors that mediate and modulate the actions of hormones in with data from a recent study (Salmi et al., 1998a) , which showed constant immunoreactivity of ER in women using the the endometrium may account for both increased proliferation and increased blood loss in women with menorhagia (Giudice, LNG-IUS for contraception. In spite of the presence of ER and endogenous oestrogen production, not only expression of 1994). However, it has to be considered that only ERα is included in our evaluations.
PR but also other ER-mediated cellular functions appear to be suppressed in LNG-exposed endometrium (Rutanen et al., To our knowledge, there is only one immunohistochemical study on endometrial sex steroid receptors in women with 1997; Salmi et al., 1998b) . This implies that the molecular mechanisms of levonorgestrel action may be more complex normal and excessive MBL (Ͼ80 ml per period) (Critchley et al., 1994) . In that study, no differences were found between than has been assumed. Indeed, the two distinct isoforms of the human PR (A and B) (Clark et al., 1987; Critchley et al. , the two groups and this was confirmed by the present study. In another study (Gleeson et al., 1993) , solid phase immunoassays 1998b) have been shown to be differentially affected by levonorgestrel (Critchley et al., 1998b) . Subtype A was actually were used to examine endometrial sex steroid receptors in menorrhagic women, and demonstrated an increased concentrafound to be increased at 12 months post-LNG-IUS insertion and was therefore thought to be the subtype of PR that mediates tion of oestrogen receptors in premenstrual endometria of women with menorrhagia.
long-term levonorgestrel action in the endometrium (Critchley et al., 1998b) . Similarly, the oestrogen receptor (ER) subtypes Use of the LNG-IUS for 6 months resulted in a significant decrease in the amount of menstrual blood loss (unpublished α and β (Mosselman et al., 1996; Kuiper et al., 1997) may be differentially expressed in levonorgestrel-exposed data), and simultaneously there was a decline in immunostaining of epithelial and stromal PRs compared with proliferatendometrium.
Levonorgestrel is known to be a very potent progestogen in ive and secretory endometria before treatment. This is
